Immunostimulants drugs - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.93 [0.68, 1.27]< 10%10 studies (10/-)68.1 %some concernlow moderatecrucial-
death or transfer to ICU 0.65 [0.35, 1.22]< 10%1 study (1/-)90.9 %NAnot evaluable crucial-
deaths 0.86 [0.70, 1.06]< 19%18 studies (18/-)91.7 %lowlow highcrucial-
deaths (time to event analysis only) 1.28 [0.68, 2.41]< 111%3 studies (3/-)21.9 %lownot evaluable highcrucial-
clinical deterioration 0.63 [0.29, 1.40]< 10%1 study (1/-)87.0 %NAnot evaluable important-
clinical improvement 1.17 [0.95, 1.44]> 153%9 studies (9/-)93.2 %some concernserious moderateimportant-
clinical improvement (14-day) 1.33 [0.63, 2.83]> 164%2 studies (2/-)77.2 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.41 [0.82, 2.45]> 165%4 studies (4/-)89.1 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.98 [0.27, 3.58]> 10%1 study (1/-)48.8 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.23 [0.98, 1.54]> 155%7 studies (7/-)96.5 %some concernserious moderateimportant-
hospital discharge 3.44 [0.64, 18.49]> 10%1 study (1/-)92.4 %NAnot evaluable important-
mechanical ventilation 0.96 [0.63, 1.45]< 10%7 studies (7/-)57.6 %some concernnot evaluable moderateimportant-
mechanical ventilation (time to event analysis only) 0.66 [0.25, 1.72]< 10%1 study (1/-)80.2 %NAnot evaluable important-
radiologic improvement (14-day) 2.33 [0.45, 12.00]> 10%1 study (1/-)84.4 %NAnot evaluable important-
viral clearance 6.97 [0.23, 210.35]> 189%2 studies (2/-)86.4 %some concernnot evaluable moderateimportant-
viral clearance by day 14 7.68 [0.34, 173.70]> 190%2 studies (2/-)89.7 %some concernnot evaluable moderateimportant-
ICU admission 0.62 [0.42, 0.92]< 10%6 studies (6/-)99.1 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.19 [0.81, 1.76]< 152%5 studies (5/-)19.0 %lownot evaluable highimportant-
superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %NAnot evaluable important-
adverse events 1.10 [0.87, 1.39]< 10%2 studies (2/-)21.8 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.